Shares of Glenmark Prescription drugs Ltd have been buying and selling within the crimson and virtually 1% decrease on Wednesday, 18 June, after the US Meals and Drug Administration (USFDA) issued Kind 483 with 5 observations for the corporate’s plant in Monroe, North Carolina.
The US drug company carried out a basic manufacturing follow (GMP) inspection of Glenmark Pharma’s plant from 9 June to 17 June 2025. The company acknowledged that the 5 observations are procedural in nature. There was no remark associated to knowledge integrity reported, it added.
Glenmark Pharma acknowledged that it will work carefully with the company to resolve the findings and would reply to the USFDA throughout the timeframe specified.
Glenmark Pharma introduced final week the worldwide launch of Brukinsa, a blood most cancers remedy medication authorized by the Medication Controller Normal of India (DCGI).
The corporate’s consolidated income for the fourth quarter climbed by 6.3% to Rs 3,256 crore from Rs 3,063 crore the prior yr. Within the March quarter, the corporate’s earnings earlier than curiosity, tax, depreciation, and amortization (EBITDA) elevated by 11.2% to Rs 561 crore, with an improved EBITDA margin of 17.2% in comparison with the earlier yr.
In fiscal yr 2025, the corporate’s consolidated income climbed by 12.8% to Rs 13,322 crore from Rs 11,813 crore the earlier yr. The corporate’s EBITDA has greater than doubled to Rs 2,531 crore, with a 17.6% margin. Glenmark Pharma’s adjusted PAT rose to Rs 1,389 crore.
Nevertheless, at 12:17 pm, the shares of Glenmark Pharma have been buying and selling 0.34% larger at Rs 1,658.80 on NSE.
Uninterested in guessing shares to commerce in day by day?
Unicorn Indicators empowers you with highly effective instruments like day by day inventory scans for Intraday, Swing & Investing, Market Predictions and way more. Obtain the Unicorn Indicators app at the moment and take management of your investments!
